PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
Authors:
- 11 March 2021
- journal article
- research article
- Published by Springer Nature in Endocrine Pathology
- Vol. 32 (3) , 408-414
Abstract
Pituitary neuroendocrine tumours (PitNETs) cause lifelong morbidity, some requiring extensive surgical intervention, radiotherapy, or chemotherapy. A small percentage still cause debilitating disease, resistant to standard treatments, and may benefit from novel therapies. We assessed PD-L1 expression in a large cohort of PitNETs to investigate whether immunotherapy could represent a rational therapeutic choice. Unselected PitNETs undergoing surgical resection were reclassified according to the WHO 2017 system and underwent PD-L1 immunohistochemistry (clone SP263) in tissue microarray format. Membranous expression was scored as 0 (no expression), 1+ (< 50% expression) and 2+ (> 50% expression). A total of 265 PitNETs underwent PD-L1 immunohistochemistry. Prominent non-specific cytoplasmic staining was noted making assessment of true membrane expression difficult. Allowing for this, 40 of 264 (15%) PitNETs demonstrated strong staining (> 50% of neoplastic cells positive). These included 5/10 (50%) somatotrophs, 7/17 (41%) lactotrophs, 2/5 (40%) mammosomatotrophs, 4/8 (50%) mixed somatotroph-lactotrophs, 3/5 (60%) PIT-1 positive plurihormonal tumours with TSH expression, 10/28 (36%) of PIT-1 positive plurihormonal tumours, and 4/10 (40%) of PIT-1 positive tumours with no hormonal expression. Only 2/32 (6%) transcription factor triple negative, hormone negative tumours, 5/113 (4%) of gonadotrophs, and 0/6 thyrotrophs or 0/30 corticotrophs showed significant staining. We conclude that PD-L1 expression is common in somatotrophs, lactotrophs, and PIT-1 positive plurihormonal PitNETs but rare in transcription factor negative, hormone negative PitNETs, gonadotrophs, and corticotrophs. If the therapeutic role of immunotherapy is to be explored in PitNETs, it may be that it is of most benefit in the PD-L1 high subgroup.Keywords
This publication has 43 references indexed in Scilit:
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With TemozolomideThe Journal of Clinical Endocrinology & Metabolism, 2015
- Succinate Dehydrogenase Deficiency Is Rare in Pituitary AdenomasAmerican Journal of Surgical Pathology, 2014
- Capture, crawl, cross: the T cell code to breach the blood–brain barriersTrends in Immunology, 2012
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatmentClinical Endocrinology, 2012
- Radiation Therapy in the Management of Pituitary AdenomasThe Journal of Clinical Endocrinology & Metabolism, 2011
- Natural History of Nonfunctioning Pituitary Adenomas and Incidentalomas: A Systematic Review and MetaanalysisThe Journal of Clinical Endocrinology & Metabolism, 2011
- Pituitary Incidentaloma: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2011
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and ExpressionThe Journal of Clinical Endocrinology & Metabolism, 2010
- Pituitary incidentalomasBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- What is the natural history of nonoperated nonfunctioning pituitary adenomas?Clinical Endocrinology, 2007